Get started
Author

R. Furie

Observed names: R Furie, R.A. Furie, Rich A. Furie
OpenAlex ID: A5113322804
High mobility group box chromosomal protein 1: A novel proinflammatory mediator in synovitis
2002 · R. Kokkola, E. Sundberg, et al. · Arthritis & Rheumatism · 290
Advancements and challenges in CAR T cell therapy in autoimmune diseases
2024 · Georg Schett, Fabian Müller, et al. · Nature Reviews Rheumatology · 252
Improvement in patient‐reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti–tumor necrosis factor therapy
2008 · E. Keystone, G. R. Burmester, et al. · Arthritis Care & Research · 105
Pos0695 Kzr-616, a Selective Immunoproteasome Inhibitor for the Treatment of Systemic Lupus Erythematosus: Results From the Completed Dose Escalation Phase 1b Portion of the Mission Study
2021 · R. Furie, S. Parikh, et al. · Annals of the Rheumatic Diseases · 13
Pos0190 Efficacy and Safety of Baricitinib in Patients With Systemic Lupus Erythematosus: Results From Two Randomised, Double-blind, Placebo-controlled, Parallel-group, Phase 3 Studies
2022 · E.F. Morand, Y. Tanaka, et al. · Annals of the Rheumatic Diseases · 10
PDF
Op0166 Alternative Renal Response Definitions in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis
2020 · Z. Amoura, P. Rémy, et al. · Annals of the Rheumatic Diseases · 7
PDF
OP0116 Effects of Blisibimod, a Subcutaneous Inhibitor of B Cell Activating Factor, in Patients with SLE
2013 · R. Furie, M. Scheinberg, et al. · Annals of the Rheumatic Diseases · 4
Pos0689 a 6-month Open-label Extension Study of the Safety and Efficacy of Intravenous Belimumab in Patients With Lupus Nephritis
2021 · R. Furie, B.H. Rovin, et al. · Annals of the Rheumatic Diseases · 3
PDF
Pos0529 Obinutuzumab Benefits Patients With Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: a Post Hoc Analysis of the Phase Ii Nobility Trial
2024 · R.A. Furie, J.A. Ross Terres, et al. · Annals of the Rheumatic Diseases · 1
Ab0518 Effect of Litifilimab on Type I Interferon (ifn) Biomarkers in Patients With Systemic Lupus Erythematosus (sle) or Cutaneous Lupus Erythematosus (cle): Result of the Lilac Phase 2 Study
2023 · R. Furie, V. Werth, et al. · Annals of the Rheumatic Diseases · 1
PDF
Pos0699 Greater Reduction in Clasi-a Scores Achieved With Biib059 Versus Placebo Independently of Disease Severity at Baseline
2021 · V. Werth, R. Furie, et al. · Annals of the Rheumatic Diseases · 1
PDF
AB0189 Geographic Differences in Demographics, Clinical Characteristics, and Standard of Care in Multinational Studies of Patients with Moderate to Severe Sle
2015 · R. Furie, M. Khamashta, et al. · Annals of the Rheumatic Diseases · 1
THU0023 Correlation of Laboratory and Clinical Parameters with British Isles Lupus Assessment Group Response in an Open-Label Extension Study of Epratuzumab in Systemic Lupus Erythematosus
2014 · R.A. Furie, M. Petri, et al. · Annals of the Rheumatic Diseases · 1
L’obinutuzumab démontre un bénéfice constant avec de nombreuses définitions du critère d’évaluation principal d’après les résultats de l’étude REGENCY chez des patients atteints de néphrite lupique active
2025 · Z. Amoura, B.H. Rovin, et al. · Revue du Rhumatisme
Op0006 Obinutuzumab Demonstrates Consistent Benefit Across Numerous Primary Endpoint Definitions Using Regency Study Results of Patients With Active Lupus Nephritis
2025 · B.H. Rovin, W.F. Pendergraft, et al. · Annals of the Rheumatic Diseases
Abs0857 Pharmacodynamic Effects of Obinutuzumab on B Cells and Serological Markers in Patients With Active Lupus Nephritis: Results From the Phase Iii Regency Study
2025 · R.A. Furie, I. Parodis, et al. · Annals of the Rheumatic Diseases
POS0170 ACHIEVEMENT OF TREAT TO TARGET MEASURES WITH UPADACITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: PHASE 2 RANDOMIZED SLEek CLINICAL TRIAL RESULTS
2025 · E. Morand, J. Merrill, et al. · Annals of the Rheumatic Diseases
Abs1125 a Phase Iii, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients With Systemic Lupus Erythematosus
2025 · E.M. Vital, Z. Amoura, et al. · Annals of the Rheumatic Diseases
Ab0982 Domains for Inclusion in a Novel Treatment Response Measure for Systemic Lupus Erythematosus (trm-sle): Results of a Modified Delphi Study
2024 · K. Connelly, R. Koelmeyer, et al. · Annals of the Rheumatic Diseases
Op0077 Longitudinal Assessment of Biomarkers in Nobility, a Randomized, Phase Ii Clinical Trial of Obinutuzumab for Treatment of Proliferative Lupus Nephritis
2024 · E.M. Vital, S.W. Tas, et al. · Annals of the Rheumatic Diseases
Effets du belimumab sur la fonction rénale, le contrôle global et les biomarqueurs du lupus systémique
2021 · Z. Amoura, R. Furie, et al. · La Revue de Médecine Interne
28 Drivers of the sle responder index (sri-5) endpoint in clinical trials of sle
2017 · K Kalunian, M Urowitz, et al.
PDF
24 A molecular signature based on ifn gene signature and serology defines two populations of patients with different baseline disease activity
2017 · M Petri, K Kalunian, et al.
PDF
Works count: 23
Citation count: 689
H-index: 6
I10-index: 5
Year
Topic
Type